Know Cancer

or
forgot password

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer


Phase 1
20 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer


Inclusion Criteria:



- Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL
progressive to current therapy who satisfy the inclusion and exclusion criteria

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer

Outcome Time Frame:

throughout the study

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

CA185-005

NCT ID:

NCT00644488

Start Date:

July 2008

Completion Date:

March 2009

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location